At a $369M market cap with negative EPS of -3 and no Forward P/E, this is not a growth story the market can handicap with traditional valuation tools—it’s a balance sheet and survival story. The Altman Z-Score of -1.9 signals material financial distress risk, while a Current Ratio of 0.6 reinforces near-term liquidity strain. Yet the stock trades at just 1.1x sales, which implies the market is already discounting severe execution and solvency risk; this is a speculative turnaround at best, not a stable compounder. Without earnings visibility and with EPS next year estimated at -$1.10, the path to profitability remains uncertain, and the absence of key valuation anchors makes this a high-risk special situation rather than a classic GARP play.